JP Morgan has kept a neutral view on Genpact while raising its price target to $45, reflecting guarded optimism amidst a divided analyst outlook and ongoing market uncertainties.
JP Morgan kept a Neutral view on Genpact while lifting its price target to $45 from $40 on October 5, 2023, a move that pointed to guarded optimism about the business even as the bank stopped short of a bullish call. GuruFocus said the new target represented a 12.5% increase and sat above the then-share price of $34.27, which it calculated as leaving the stock about 27.2% below its GF Value estimate of $47.06.
The broader picture around Genpact has remained mixed. TipRanks showed that other firms have also disagreed on the shares, with Robert W. Baird cutting its target to $38 from $45 and Citi trimming its estimate to $32 from $35, while William Blair and Needham kept Buy ratings in place. That spread suggests analysts see value in Genpact’s business model but differ on how quickly it can translate into share price gains.
GuruFocus described Genpact as a technology and services company focused on digital transformation, data-led operations and AI-enabled offerings, with a large share of revenue tied to India. Its GF Score of 83 out of 100 points to solid overall fundamentals, led by strong profitability and growth scores, though momentum remains weak. The stock’s low momentum reading indicates that, despite healthy operating traits, investor enthusiasm has been limited.
Sentiment among large holders has also been uneven. GuruFocus said eight gurus held the stock, with three adding exposure and six reducing it in recent quarters, while no insider buys or sales were reported over the previous three months. More recently, in 2024 and 2026, other brokers adjusted their views as well: Mizuho raised its target to $45 after strong third-quarter results, Jefferies cut its target to $45 from $56 but kept a Buy rating, and Needham lowered its target to $50 while maintaining a Buy call. Taken together, the calls show a stock that continues to attract interest, but one still facing doubts about the speed and durability of its next leg higher.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
